Want to see ACOG full AI Analyst Report?
ACOG Stock Chart & Stats
$7.90
$0.68(8.61%)
At close: 4:00 PM EDT
$7.90
$0.68(8.61%)
Day’s Range― - ―
52-Week Range$4.50 - $10.00
Previous Close$8.58
Volume108.17K
Average Volume (3M)87.53K
Market Cap
$192.52M
Enterprise Value$115.77
Total Cash (Recent Filing)$41.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Dec 01, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding21,777,868
10 Day Avg. Volume111,240
30 Day Avg. Volume87,535
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.84
Price to Sales (P/S)11.24
P/FCF Ratio-5.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.25Price Target Upside118.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.37
Revenue Forecast (FY)$22.08M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue ScalingSustained, multi-quarter revenue acceleration signals genuine early commercial traction rather than a one-off spike. Rising unit demand and expanding prescriber base imply the product is gaining market acceptance, supporting a path to scale where fixed R&D and commercial costs can be leveraged over time.
High Gross Margins And Strong Repeat UseVery high gross margins plus high repeat prescription rates create durable unit economics as volume grows. Sticky prescribing and institutional repeat orders reduce acquisition churn, improve lifetime revenue per prescriber, and make profitable scaling more attainable if commercial growth continues.
Low Leverage And Meaningful Cash BufferA debt-free capital structure and a multi‑month cash reserve materially lower near-term funding distress risk. This financial flexibility supports continued investment in commercialization and trials without immediate refinancing pressure, preserving strategic optionality during the growth phase.
Bears Say
Significant Cash BurnLarge and sustained negative operating and free cash flows mean the company will likely need external financing to fund planned trials and commercialization. Recurrent dilution risk and potential constraints on strategic choices persist until operations become cash-generative or spending is markedly reduced.
Deep Unprofitability And Rising Operating SpendOperating costs greatly exceed current revenue, and management plans elevated full-year spend to support launch and trials. Without sustained top-line scaling or sharp operating leverage, persistent losses will erode equity and delay sustainable profitability, pressuring long-term returns.
Commercial Expansion Tied To Clinical And Payer MilestonesBroader formulary access and payer uptake hinge on near‑term clinical readouts and rollout of PBM implementation. Delays or weaker results could materially slow adoption and revenue scale, creating execution risk that is structural until clinical evidence and payer coverage broaden reliably.
Alpha Cognition Inc News
ACOG FAQ
What was Alpha Cognition Inc’s price range in the past 12 months?
Alpha Cognition Inc lowest stock price was $4.50 and its highest was $10.00 in the past 12 months.
What is Alpha Cognition Inc’s market cap?
Alpha Cognition Inc’s market cap is $192.52M.
When is Alpha Cognition Inc’s upcoming earnings report date?
Alpha Cognition Inc’s upcoming earnings report date is Dec 01, 2026 which is in 105 days.
How were Alpha Cognition Inc’s earnings last quarter?
Alpha Cognition Inc released its earnings results on Aug 13, 2026. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.392 by -$0.008.
Is Alpha Cognition Inc overvalued?
According to Wall Street analysts Alpha Cognition Inc’s price is currently Undervalued.
Does Alpha Cognition Inc pay dividends?
Alpha Cognition Inc does not currently pay dividends.
What is Alpha Cognition Inc’s EPS estimate?
Alpha Cognition Inc’s EPS estimate is -0.35.
How many shares outstanding does Alpha Cognition Inc have?
Alpha Cognition Inc has 21,777,868 shares outstanding.
What happened to Alpha Cognition Inc’s price movement after its last earnings report?
Alpha Cognition Inc reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.392. Following the earnings report the stock price went up 2.433%.
Which hedge fund is a major shareholder of Alpha Cognition Inc?
Currently, no hedge funds are holding shares in ACOG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Cognition Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.25 (118.35% Upside)
$17.25 (118.35% Upside)
Blogger Sentiment
Bullish
ACOG Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 16.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
42.99%
Trailing 12-Months
Company Description
Alpha Cognition Inc
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
ACOG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum for ZUNVEYL: rapid sequential revenue growth (71% QoQ), healthy gross margins (~94%), improving net loss, robust organic demand (37% bottle growth) and encouraging prescriber/facility repeat metrics. Management is deliberately investing to scale commercial capabilities and evidence generation (BEACON positive; CONVERGE topline expected Q3). Key challenges are slower-than-expected payer/formulary activation, limited contracted coverage (~16%), and dependence on upcoming data and policy-driven plan behavior; the company remains unprofitable but projects operating profitability in 2027. On balance, the positive commercial execution and financial improvements outweigh the access and timing headwinds, with upside from future payer conversions.View all ACOG earnings summariesACOG Stock 12 Month Forecast
Average Price Target
$17.25
▲(118.35% Upside)
Technical Analysis
Ownership Overview
20.16% Insiders
0.06% Mutual Funds
46.34% Other Institutional Investors
33.44% Public Companies and
Individual Investors